Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 antibody-drug conjugate DB-1303

An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DB-1303, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, the cytotoxic agent inhibits tumor cell proliferation through an as of yet undisclosed mechanism of action (MoA). HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC DB-1303
anti-HER2 ADC DB-1303
DITAC DB-1303
Code name:DB 1303
DB-1303
DB1303
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search